Nothing Special   »   [go: up one dir, main page]

PL3003268T3 - Trwałe doustne roztwory dla połączonych api - Google Patents

Trwałe doustne roztwory dla połączonych api

Info

Publication number
PL3003268T3
PL3003268T3 PL14727848T PL14727848T PL3003268T3 PL 3003268 T3 PL3003268 T3 PL 3003268T3 PL 14727848 T PL14727848 T PL 14727848T PL 14727848 T PL14727848 T PL 14727848T PL 3003268 T3 PL3003268 T3 PL 3003268T3
Authority
PL
Poland
Prior art keywords
oral solutions
stable oral
combined api
api
combined
Prior art date
Application number
PL14727848T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Viviane Bertrand
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of PL3003268T3 publication Critical patent/PL3003268T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PL14727848T 2013-06-05 2014-06-05 Trwałe doustne roztwory dla połączonych api PL3003268T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13170583 2013-06-05
EP14727848.5A EP3003268B1 (en) 2013-06-05 2014-06-05 Stable oral solutions for combined api
PCT/EP2014/061664 WO2014195394A1 (en) 2013-06-05 2014-06-05 Stable oral solutions for combined api

Publications (1)

Publication Number Publication Date
PL3003268T3 true PL3003268T3 (pl) 2019-01-31

Family

ID=48569977

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14727848T PL3003268T3 (pl) 2013-06-05 2014-06-05 Trwałe doustne roztwory dla połączonych api

Country Status (28)

Country Link
US (2) US10300015B2 (pl)
EP (1) EP3003268B1 (pl)
JP (1) JP6300906B2 (pl)
KR (1) KR102203491B1 (pl)
CN (2) CN105473131A (pl)
AU (1) AU2014276856B2 (pl)
BR (1) BR112015030268B1 (pl)
CA (1) CA2913331C (pl)
CY (1) CY1120758T1 (pl)
DK (1) DK3003268T3 (pl)
EA (1) EA029478B1 (pl)
ES (1) ES2691309T3 (pl)
HK (1) HK1223278A1 (pl)
HR (1) HRP20181607T1 (pl)
HU (1) HUE040023T2 (pl)
IL (1) IL242735B (pl)
LT (1) LT3003268T (pl)
MX (1) MX367210B (pl)
NZ (1) NZ714684A (pl)
PL (1) PL3003268T3 (pl)
PT (1) PT3003268T (pl)
RS (1) RS57906B1 (pl)
SG (1) SG11201509824UA (pl)
SI (1) SI3003268T1 (pl)
TR (1) TR201815059T4 (pl)
UA (1) UA115811C2 (pl)
WO (1) WO2014195394A1 (pl)
ZA (1) ZA201508675B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP3003268B1 (en) * 2013-06-05 2018-07-25 Pharnext Stable oral solutions for combined api
EA201691602A1 (ru) 2014-02-11 2017-03-31 Фарнекст Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
EP3509592A4 (en) 2016-09-09 2020-07-22 Cutispharma, Inc. SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN
CN106389313A (zh) * 2016-10-08 2017-02-15 安徽省逸欣铭医药科技有限公司 一种巴氯芬口服液组合物
EP3582765B1 (en) 2017-10-10 2021-04-28 Vertice Pharma, LLC Midodrine hydrochloride oral solution and uses thereof
US10952981B2 (en) * 2019-05-27 2021-03-23 Slayback Pharma Llc Liquid pharmaceutical compositions of baclofen for oral administration
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10610502B1 (en) 2019-08-30 2020-04-07 Metacel Pharmaceuticals, LLC Oral baclofen solutions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
RU2184570C2 (ru) 1997-09-30 2002-07-10 Дайити Фармасьютикал Ко., Лтд. Препараты для орального введения
JP2002526417A (ja) 1998-10-02 2002-08-20 セルトリックス ファーマシューティカルズ,インコーポレイテッド 非甲状腺性疾患の治療方法
WO2002049607A2 (en) * 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
US20030229111A1 (en) 2002-03-14 2003-12-11 Benjamin Oshlack Naltrexone hydrochloride compositions
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
CA2495917A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
CA2522471A1 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
US20060194826A1 (en) 2003-09-25 2006-08-31 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
JP4994039B2 (ja) 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
FR2865648B1 (fr) 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2674610C (en) 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) * 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
LT2796132T (lt) 2011-03-01 2018-10-10 Pharnext Neurologinių sutrikimų terapija baklofeno ir akamprosato pagrindu
EP3003268B1 (en) 2013-06-05 2018-07-25 Pharnext Stable oral solutions for combined api
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
EP3003268B1 (en) 2018-07-25
US10849851B2 (en) 2020-12-01
AU2014276856B2 (en) 2018-11-15
EA201592227A1 (ru) 2016-04-29
JP6300906B2 (ja) 2018-03-28
CN105473131A (zh) 2016-04-06
JP2016521698A (ja) 2016-07-25
CY1120758T1 (el) 2019-12-11
LT3003268T (lt) 2018-12-10
HRP20181607T1 (hr) 2018-12-28
MX2015016676A (es) 2016-06-23
UA115811C2 (uk) 2017-12-26
EA029478B1 (ru) 2018-03-30
CA2913331A1 (en) 2014-12-11
NZ714684A (en) 2020-05-29
US20190290578A1 (en) 2019-09-26
KR102203491B1 (ko) 2021-01-14
IL242735B (en) 2019-10-31
HK1223278A1 (zh) 2017-07-28
ZA201508675B (en) 2017-07-26
HUE040023T2 (hu) 2019-02-28
PT3003268T (pt) 2018-11-08
MX367210B (es) 2019-08-08
AU2014276856A1 (en) 2015-12-17
BR112015030268B1 (pt) 2023-01-31
CA2913331C (en) 2021-08-24
ES2691309T3 (es) 2018-11-26
CN113209101A (zh) 2021-08-06
SI3003268T1 (sl) 2019-01-31
DK3003268T3 (en) 2018-11-05
EP3003268A1 (en) 2016-04-13
TR201815059T4 (tr) 2018-11-21
BR112015030268A2 (pt) 2017-07-25
SG11201509824UA (en) 2015-12-30
US10300015B2 (en) 2019-05-28
US20160113867A1 (en) 2016-04-28
KR20160048040A (ko) 2016-05-03
RS57906B1 (sr) 2019-01-31
WO2014195394A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
HRP20181607T1 (hr) Stabilne oralne otopine za kombinirane aktivne farmaceutske sastojke
EP3065716C0 (en) FORMULATIONS
IL239203A0 (en) A semifluorocarbon compound containing a contrast agent
EP2889350A4 (en) ADHESIVE COMPOSITION
PT3626270T (pt) Tratamento de doenças cardiovasculares
GB201305825D0 (en) New use
EP3006525A4 (en) ASPHALT-URETHANE COMPOSITION
SG11201604769VA (en) Ship-shaped structure
GB201319792D0 (en) Formulations
GB201518344D0 (en) No details present
HK1215678A1 (zh) 口腔用組合物
HK1214951A1 (zh) 眼用製劑
EP3066178A4 (en) GREASE COMPOSITION
GB201404505D0 (en) Oral anti-parasitic composition
GB201313900D0 (en) Tumour-targeted theranostic
GB201414328D0 (en) None
HUP1300496A2 (hu) Stabil kombinációs gyógyszerkészítmény
GB201308933D0 (en) Paediatric composition
GB201305103D0 (en) An oral dosage form
GB201301774D0 (en) Composition
EP3037100A4 (en) MEANS TO PREVENT MUSCLE ATROPHY
GB201410951D0 (en) None
SG2013095815A (en) Mirror-monitor (variants)
GB201310280D0 (en) Odontalgic preparation
GB201315861D0 (en) Bob holdness